Cytomx Therapeutics Inc (CTMX) Institutional Ownership Tracker (Q2 2026)

CTMX ranks #3283 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

179 institutions disclose a position in CTMX, but none treat it as a major bet — even Kynam Capital Management, LP, its most concentrated holder, allocates just 4.5% of its own portfolio to it.

Bank Of America CORP /de/ has added to its CTMX position for two straight quarters, increasing it by $52.8M to reach $56.6M today.

Venrock Adviser, LLC has trimmed its CTMX position for two straight quarters, cutting it by $47.6M while still holding $18.7M.

CTMX is up 1.4% today, and institutions have been net buyers of $143.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CTMX reported a net loss of $79.7M over the trailing twelve months.

• Not yet profitable — net loss of $79.7M over the trailing twelve months
• Revenue declined 87.0% year over year
• Net income declined year over year, from $48.0M to -$79.7M
• Operating cash flow was negative, using $75.6M in cash
• Current ratio of 3.09x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.53x equity — within a conventional range